Reductions in HbA1c, systemic inflammatory markers, as well as proinsulin to insulin ratios in T2DM patients, were demonstrated after 13 weeks of Anakinra administration, a recombinant IL-1R antagonist [35]. The gene discussed is IL1R1; the disease is type 2 diabetes mellitus.